Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial

BACKGROUND: Low-dose interleukin-2 (ld-IL-2) enhances regulatory T-cell (Treg) function in auto-inflammatory conditions. Neuroinflammation being a pathogenic feature of amyotrophic lateral sclerosis (ALS), we evaluated the pharmacodynamics and safety of ld-IL-2 in ALS subjects. METHODS: We performed...

Descripción completa

Detalles Bibliográficos
Autores principales: Camu, William, Mickunas, Marius, Veyrune, Jean-Luc, Payan, Christine, Garlanda, Cecilia, Locati, Massimo, Juntas-Morales, Raul, Pageot, Nicolas, Malaspina, Andrea, Andreasson, Ulf, Kirby, Janine, Suehs, Carey, Saker, Safa, Masseguin, Christophe, De Vos, John, Zetterberg, Henrik, Shaw, Pamela J, Al-Chalabi, Ammar, Leigh, P Nigel, Tree, Timothy, Bensimon, Gilbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502670/
https://www.ncbi.nlm.nih.gov/pubmed/32651161
http://dx.doi.org/10.1016/j.ebiom.2020.102844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502670/
https://www.ncbi.nlm.nih.gov/pubmed/32651161
http://dx.doi.org/10.1016/j.ebiom.2020.102844

Ejemplares similares